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Summary In the present work we reviewed recent advances concerning
neuroprotective=neurotrophic effects of acute or chronic nicotine exposure,
and the signalling pathways mediating these effects, including mechanisms
implicated in nicotine addiction and nAChR desensitization. Experimental
and clinical data largely indicate long-lasting effects of nicotine and nicotinic
agonists that imply a neuroprotective=neurotrophic role of nAChR activation,
involving mainly a7 and a4b2 nAChR subtypes, as evidenced using selective
nAChR agonists. Compounds interacting with neuronal nAChRs have the
potential to be neuroprotective and treatment with nAChR agonists elicits
long-lasting neurotrophic effects, e.g. improvement of cognitive performance
in a variety of behavioural tests in rats, monkeys and humans. Nicotine
addiction, which is mediated by interaction with nACh receptors, is believed
to involve the modification of signalling cascades that modulate synaptic
plasticity and gene expression. Desensitization, in addition to protecting cells
from uncontrolled excitation, is recently considered as a form of signal
plasticity. nAChR can generate these longe-lasting effects by elaboration of
complex intracellular signals that mediate medium to long-term events crucial
for neuronal maintenance, survival and regeneration. Although a comprehen-
sive survey of the gene-based molecular mechanisms that underlie nicotine
effects has yet not been performed a growing amount of data is beginning to
improve our understanding of signalling mechanisms that lead to neurotrop-
hic=neuroprotective responses. Evidence for an involvement of the fibroblast
growth factor-2 gene in nAChR mechanisms mediating neuronal survival,
trophism and plasticity has been obtained. However, more work is needed to
establish the mechanisms involved in the effects of nicotinic receptor subtype
activation from cognition-enhancing and neurotrophic effects to smoking
behaviour and to determine more precisely the therapeutic objectives in po-
tential nicotinic drug treatments of neurodegenerative diseases.
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Nicotinic acetylcholine receptors
Neuronal nicotinic acetylcholine receptors (nAChRs) be-
long to the superfamily of ligand-gated ion channels and
are located in both the peripheral and central nervous sys-
tems. They are composed of five subunits and at present
nine nicotinic receptor a subunits (a2–a10) and three b
subunits (b2–b4) have been identified, each encoded by a
different gene (Picciotto et al., 2001). In heterologous ex-
pression nAChR can contain more than one of the a2,
a3, a4 or a6 subunits and=or both b2 and b4 subunits as
well (Couturier et al., 1990). Accordingly, several different
combinations of nAChR subunit mRNA and=or proteins
have been identified in the central and peripheral nervous
structures (Le Novere et al., 2002). The subunits a7, a8,
a9, and a10 subunits can form homomeric receptors (Le
Novere and Changeux, 1995). These multiple combinations
of nAChR subunits possess distinct pharmacological and
physiological properties. Thus nAChRs show different affin-
ity for ligands, variability of permeability for cations and
rate of desensitization (Changeux et al., 1998).
The distribution of neuronal nAChR in the CNS differs
for the different subunits and the most common subunit
arrangements within the central nervous system include
the a4=b2 type receptor and the a7 type receptor. The a4
and b2 are present in the entire nervous system (Wada
et al., 1989). By contrast the distribution of a7 subunit
mRNA is restricted to certain layers of cerebral cortex, to
the hypothalamus, hippocampus and to some brain stem
nuclei (Seguela et al., 1993). nAChR containing other sub-
units are localized in important brain regions, but they are
less abundant. The a2 subunit is expressed at very low
levels in restricted brain regions (Wada et al., 1989). The
a5 subunit mRNA is expressed at high levels in neurons
of the subiculum, pre- and parasubiculum, substantia nigra,
ventral tegmental area, and weakly expressed in the cerebral
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cortex (Wada et al., 1990). The a3 and b4 subunits, which
form the main nAChR responsible for nicotinic synaptic
transmission in autonomic ganglia, are highly enriched in
the medial habenula (Le Novere and Changeux, 1995). The
a6 and b3 subunits are highly and selectively enriched in
catecolaminergic nuclei, such as the dopaminergic neurons
of the substantia nigra, and the noradrenergic neurons of
the locus coeruleus (Le Novere and Changeux, 1995). It
has therefore been proposed that they can form, together
with other subunits, the nAChR responsible for catechol-
amine release in the basal ganglia and hippocampus (Le
Novere and Changeux, 1995). nAChRs located presynapti-
cally regulate the release of serotonin, dopamine, norepi-
nephrine (Summers and Giacobini, 1995), glutamate (Gray
et al., 1996), gamma-aminobutyric acid (Ji and Dani, 2000)
and acetylcholine (Tani et al., 1998). The a4=b2 nicotinic
receptor binds nicotine with high affinity, while the a7
nicotinic receptor binds nicotine with a low affinity (Lena
and Changeux, 1998). When agonists bind to the nAChR,
the receptor complex undergoes a conformational change
in its structure, which allows the channel gate to open,
permitting the passage of cations through the channel pore.
However functionally, the nAChR complex can exist in
three conformational states, which are dynamically regu-
lated by exposure to the agonist: closed, open and desensi-
tized states.
Neuroprotective=neurotrophic effects of nAChR
activation
Recently an increasing number of potent nAChR agonists
have been used in experimental research and clinical trials,
and have been found displaying efficacy and=or a more
selective affinity than nicotine for neuronal nAChR sub-
types, some of which are considered potential candidates
not only for the treatment of neurodegenerative disease such
as Alzheimer’s disease (AD) and Parkinson’s disease (PD)
(Bannon et al., 1998), but also, as discussed below, for cog-
nitive disorders associated with Schizophrenia (Kem, 2000).
A growing number of in vivo and in vitro findings have
shown that nAChRs activation have the potential to be
neuroprotective=neurotrophic.
Evidence in vivo
nAChRs have important roles in development and synaptic
plasticity (Broide and Leslie, 1999; Levin et al., 1999). a7
nAChRs are expressed early in development and have been
shown to be important for the control of neurite outgrowth,
and are involved in events of synaptic remodelling in the
adult nervous system (Pugh and Berg, 1994). The high
concentration of a7 receptors in the hippocampus, a region
of the brain that is critical for memory, also supports a role
for a7 receptors in the modulation of synaptic plasticity
and in memory formation (Small et al., 2001). Nicotinic
receptors can modulate the rhythmic activity important for
synaptic plasticity, the basis for learning and memory
(Huerta and Lisman, 1993).
Many studies have analysed the effect of nAChR ago-
nists and antagonists on cognitive performance in a vari-
ety of behavioural tests in rats, monkeys and humans, and
their specific involvement in cognitive function, such as
attention, learning, sensory perception, memory consoli-
dation and arousal has been reported (Levin and Simon,
1998). The nAChR agonist nicotine improves cognition
for prolonged periods in non-human primates and in
rodents even after nicotine discontinuation (Gould and
Stephen, 2003; Buccafusco et al., 2005). By contrast, a
blockade of nicotinic receptors by a nicotinic receptor
antagonist impairs memory function (Levin and Rezvani,
2000).
Performance in attention and working memory tasks is
improved by nicotine (Gioanni et al., 1999; Levin et al.,
2002), and involves multiple brain areas, such as hip-
pocampus, amygdala, and particularly the prefrontal cor-
tex that has been implicated in attention and working
memory and goal-directed behaviour (Groenewegen and
Uylings, 2000). Epibatidine has been found to induce Long-
term potentiation (LTP), improve memory and learning in
human and experimental animal models and to be neuro-
protective in several in vitro models (Jonnala et al., 2002)
and both a7 and a4b2 nAChRs are essential for these
effects. The GTS-21 nicotinic agonist with potent func-
tional selectivity for the a7 nAChR subtype improves mem-
ory performance in several tests, such as one-way active
avoidance, Lashley III maze testing, and 17 arm radial maze
test performance in aged rats, and improve cognitive and
perceptual disturbances in schizophrenia (Arendash et al.,
1995). The nicotinic agonist SIB-1508Y, selective for
a4b2, and the nicotinic agonist SIB-1553A, active at b4
nAChRs, exhibit ability to improve cognitive activity and
learning in a variety of models and to promote locomotor
activity (Vernier et al., 1999), with long-lasting effects, in
chronic low-dose MPTP-treated monkeys (Schneider et al.,
2003). In addition, functional magnetic resonance imaging
studies have shown increased activation of frontal net-
works by nicotine administration during attention tasks
(Lawrence et al., 2002). Nicotinic receptor function may
also be critical for maintenance of cognitive function dur-
ing aging. Increased neurodegeneration is seen in aged
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b2 subunit knockout mice and is associated with learn-
ing deficits as shown during different conditioning tasks
(Picciotto et al., 2001).
The mechanism of the persisting effects of nAChR acti-
vation is currently unknown, although the involvement of
an alteration in nAChR expression or of interactions with
other transmitter systems has been suggested (Levin and
Simon, 1998). Recently we have taken into consideration
the possibility that this persistence of nicotine effects could
also be related to the increased levels of neurotrophic fac-
tors observed following nAChR agonist treatment in differ-
ent experimental models (Belluardo et al., 1998, 1999b,
2000).
Neuroprotective effects of nAChR activation have been
shown in different models with lesions of septohippo-
campal or nigrostriatal systems. Nicotinic agonists protect
against neocortical neuronal cell loss induced by nucleus
magnocellularis lesions in the rats and delayed hippocam-
pal CA1 subregion neuronal death by ischemia (Nanri
et al., 1998) and against septal cholinergic neurons death
following fimbrial transaction (Martin et al., 2004), and
septohippocampal lesion with induced deficits in spatial
memory (Decker et al., 1994b, 1995) or working memory
(Levin et al., 1993). Prenatal nicotine exposure resulted in a
trophic influence on cerebral cortex development character-
ized by premature increases in cholinergic projections
based on analysis of choline acetyltransferase (Navarro
et al., 1989).
Chronic nicotine treatment counteracts the disappear-
ance of tyrosine-hydroxylase-immunoreactive or elimi-
nates asymmetry in striatal glucose utilization in the
mesostriatal dopamine system after partial hemitransec-
tion in the rat (Janson et al., 1988a, 1989; Janson and
Moller, 1993; Jeyarasasingam et al., 2002), and protects
against neurodegeneration of dopaminergic neurons in the
MPTP model (Janson et al., 1988b) and the meth-amphet-
amine mice model of Parkinson’s disease (Maggio et al.,
1998).
Evidence in vitro
There exist numerous model systems in which nicotine has
shown protective effects on neurons, including exposure
to cytotoxic insults of glutamate, b-amyloid or 6-OHDA
(Ryan et al., 2001). Nicotine induces protection of cultured
cortical and striatal neurons against cytotoxicity mediated
by NMDA and AMPA receptors (Kaneko et al., 1997), and
of cultured hippocampal and cerebellar neurons against
kainic acid induced neurotoxicity (Semba et al., 1996).
This nAChR neuroprotection against glutamate cytotox-
icity seems to be mediated by their inhibitory action on
NO-formation (Shimohama et al., 1996). Other studies
have shown that nicotine rescues PC12 cells from death
induced by NGF deprivation (Jonnala et al., 2002). Nico-
tine has recently been shown to inhibit Ab aggregation by
preventing the conversion from a- helix to b-sheet confor-
mations (Salomon et al., 1996). Nicotine was found to
prevent Ab toxicity in hippocampal neurons (Zamani and
Allen, 2001) and in cortical neurons (Shimohama and
Kihara, 2001), and it has been suggested that nicotine-
induced protection from Ab toxicity is mediated by the
phosphatidylinositol 3-kinase cascade (Kihara et al., 2001).
Nicotine also inhibits Ab induced phospholipase A2 acti-
vation (Singh et al., 1998). Taken together the results of
nicotine inhibition of Ab toxicity in cell culture suggested
the possibility that the nAChR may be a therapeutic target
in AD.
Clinical evidence
Parkinson’s disease and Alzheimer disease – Epidemiological
and clinical studies have for a long time suggested a poten-
tial neuroprotective=neurotrophic role of nicotine in neu-
rodegenerative disease, such as AD and PD (Quik, 2004;
Newhouse et al., 2004). During the progression of AD,
cholinergic inputs degenerate and the number of nAChRs
in some areas decreases (Gotti and Clementi, 2004) and
high affinity nAChR of the a4b2 subtype, are significantly
lost in AD (Court et al., 2001). This loss likely occurs early
in the disease and is probably not true for a7-nAChR
(Martin-Ruiz et al., 1999) although a loss of a7-nAChRs
in AD has been reported (Banerjee et al., 2000). This loss
of nicotinic mechanisms, which modulates the gain and
accuracy of synapses and modulates the excitability of cir-
cuits, is likely to contribute to the overall cognitive deficits
associated with AD. Therefore cognitive changes in AD, in-
cluding memory loss, are also likely to be caused by changes
in synaptic plasticity in addition to non-specific neurotoxicity
and=or cell loss (Small et al., 2001).
Clinical studies have revealed that nicotine is effective in
ameliorating memory and attention deficits in AD patients
(Newhouse et al., 2001), and to improve learning and mem-
ory in normal humans (Warburton et al., 1986). Numerous
studies now demonstrate that chronic nicotine exposure
induces increased numbers of CNS nAChR in animals
and in human smokers in vivo (Wonnacott, 1990) and this
up-regulation of receptor number has been proposed to be
responsible for nicotine’s neuroprotective action (Jonnala
and Buccafusco, 2001). ABT-594 and ABT-418, potent and
selective agonists for the a4b2 subtype (Bannon et al.,
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1998) are 3–10-fold more potent than nicotine as to mem-
ory-enhancing actions (Decker et al., 1994a) and improve
in subjects with moderate AD deficits in total recall in a
verbal learning task, in a selective reminding task, and in
non-verbal tasks such as spatial learning and memory and
repeated acquisition.
Treatments with cholinesterase inhibitors, such as phy-
sostigmine, have shown cognitive improvements (De La
Garza, 2003). Recently galantamine, a modest acetylcholi-
nesterase inhibitor and allosteric potentiating ligand at
nAChRs, has shown neuroprotective effects against a vari-
ety of cytotoxic agents, such as b-amyloid, glutamate and
sustained cholinergic stress in vivo (Geerts, 2005) and ef-
fects on memory, hippocampal plasticity, and elevates the
number of nicotinic receptors within the hippocampus and
neocortex (Barnes et al., 2000). In patients with AD, galan-
tamine improves cognitive functional and behavioural
symptoms (Maelicke et al., 2001). There is ample evidence
that these effects of galantamine are mediated through
allosteric potentiation of the a7 subunits with the addi-
tional benefit of a lower degree of receptor desensitization
(Maelicke et al., 2001). Taken together, the loss of nAChRs
associated with AD, with the ability of nicotine to upregu-
late its receptors and the epidemological data showing
smokers to be at less risk of AD than non smokers, are
consistent with the hypothesis of nicotine receptor involve-
ment in neuroprotective=neurotrophic functions (Perry et al.,
1999).
Like for AD an inverse association between cigarette
smoking and PD has been reported (Baron, 1986). Accord-
ing to epidemiological studies, it has been shown that
cigarette smoking may have therapeutic implications in
PD (Baron, 1986) with substantial improvement of the PD
symptoms (Kelton et al., 2000), and acute i.v. nicotine
improved reaction time, speed of processing and tracking
errors, but not selective attention and semantic retrieval
(Fratiglioni and Wang, 2000). Based on the epidemiologi-
cal studies and the neuroprotective actions of nicotine in
animal models of PD (Janson et al., 1988a, b; Fuxe et al.,
1990) the potential role of nAChRs as targets for treatment
of this disease has been raised (Belluardo et al., 2000;
Burghaus et al., 2003), including the specific treatment of
cognitive dysfunction associated with PD (Forgacs and
Bodis-Wollner, 2004). Some of these effects on learning
and memory may not only be caused by neurotrophic
actions by nicotine and other nicotinic receptor agonists,
but may also be mediated by the enhancement of dopami-
nergic and noradrenergic function via the ability of nico-
tinic receptor agonists to enhance the release of dopamine
and norepinephrine in the brain including the striatum
(Summers et al., 1997; Andersson et al., 1981; Fuxe et al.,
1989), as well as to increases in tyrosine hydroxylase
and dopamine b-hydroxylase mRNA levels (Gueorguiev
et al., 2000). Therefore, treatment with nicotine, or pref-
erably selective nicotinic agonists, could attenuate nigro-
striatal damage and reduce PD progression and thus
provide neuroprotective effects by selectively stimulating
nAChR subtypes as well as improve PD symptoms by in-
creasing dopamine release and synthesis (Kelton et al.,
2000; Lichtensteiger et al., 1982; Kita et al., 1992;
Andersson et al., 1981; Fuxe et al., 1986).
Schizophrenia – Over the last twenty years, a high inci-
dence of smoking has been observed in subjects suffering
from schizophrenia (Sacco et al., 2004) and clinical data
suggested that nicotine improves certain cognitive and sen-
sory abnormalities associated with schizophrenia such as
deficits in sensory gating (Ripoll et al., 2004; Tanabe et al.,
2005). Data available suggested that nicotine improves
attention and inhibitory functions in hippocampus and cin-
gulate gyrus with involvement of GABAergic mechanisms
(Tanabe et al., 2005). Furthermore, a partial a7 agonist im-
proves auditory P50 suppression in schizophrenia (Koike
et al., 2005) and it has been indicated to be reasonable
candidates for the treatment of cognitive and perceptual
disturbances in schizophrenia (Koike et al., 2005; Deutsch
et al., 2005), since inter alia a7 nicotinic receptor activa-
tion may create a glutamatergically mediated increase in
dopamine release in the prefrontal cortex, and in area impli-
cated in the development of negative symptoms in patients
with schizophrenia (Nomikos et al., 2000). Recent studies
have shown that also galantamine improves the cognitive
performances of patients with refractory schizophrenia hav-
ing auditory hallucinations and a disorganized form of
schizophrenia (Allen and McEvoy, 2002). Therefore, the
alleviation of certain symptoms of some forms of schizo-
phrenia induced by nicotine could explain the high incidence
of smoking among schizophrenic patients and suggests that
nicotine intake by cigarette consumption may be a form
of self-medication. It is of substantial interest that there
exists a differential modulation of gene expression in
NMDA postsynaptic densities in schizophrenic smokers
vs. control smokers (Mexal et al., 2005). It is also possible
to conceive that neurotrophic actions of nicotinic agonists
can be involved in antischizophrenic actions in view of the
neurodevelopmental theory of schizophrenia (Lipska, 2004;
Freedman, 2005), since nicotinic receptors and FGF-2 exist
in the subependymal layer rich in neuronal progenitor cells
(Mudo’ et al., 2005).
Taken together the available experimental and clinical
data largely indicate long-lasting beneficial effects of nico-
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tine and nicotinic agonists that imply a neuroprotective=
neurotrophic role of nAChR activation, giving these recep-
tors a therapeutic role in PD and AD. In addition, a7 ago-
nists may have a therapeutic potential in schizophrenia.
Nicotine addiction and neuroplasticity
Brain nAChRs distribute to postsynaptic, as well as to pre-,
peri- and other, sites, where they may modulate the neuro-
transmitter release, synapse action and neuronal activity, play-
ing important roles in many physiological processes including
neuron development, learning and memory, and reward
responses as well as in addiction development (Dani et al.,
2001). Addictive drugs produce forms of structural plasticity
similar to those associated with other forms of experience-
dependent plasticity. Nicotine addiction, which is mediated by
interaction with nAChRs, is believed to involve the modifica-
tion of signalling cascades that modulate synaptic plasticity
and gene expression, as proposed for other drugs of abuse
(Dani et al., 2001; Nestler, 2002).
A growing body of evidence has shown that drugs of
abuse can activate memory mechanisms in the circuits of
the mesolimbic reward center (Nestler, 2001; Samaha and
Robinson, 2005). It has been reported that nicotine in the
ventral midbrain (VTA), via MLA-sensitive nAChR, stim-
ulates both glutamatergic terminals and DA neurons
directly, potentiating excitatory transmission in the VTA
and replace presynaptic stimulation completely in LTP
induction, generating synaptic plasticity (Mansvelder
and McGehee, 2000). The glutamatergic input to the DA
neurons can undergo LTP in response to pairing of pre-
and postsynaptic stimulation, and this process is depen-
dent on NMDA receptor activation (Bonci and Malenka,
1999).
A limited exposure to nicotine is sufficient to induce
lasting changes in the circuitry of the mesolimbic DA
reward system as shown in human adolescents express-
ing behaviours that support the observations of lasting
changes in synaptic activity by a single exposure to nico-
tine (Mansvelder and McGehee, 2000), or initial symptoms
of nicotine dependence after smoking of only a few ciga-
rettes (DiFranza and Wellman, 2003). Early on acute
nicotine injections and acute intermittent exposure to ciga-
rette smoke was found to increase DA turnover and release
in certain limbic DA nerve terminal systems of the nucleus
accumbens and the olfactory tubercle (Andersson et al.,
1981; Fuxe et al., 1986). With continued nicotine exposure,
plastic molecular alterations in central DA systems might
underlie the continued propensity to consume nicotine by
inducing craving, the aversive effects of withdrawal, and
aberrant incentive-salience attribution to environmental stim-
uli that are associated with nicotine. The synaptic mech-
anisms that nicotine activates within the DA reward system
are likely to underlie the early steps of nicotine dependence
and it is one of the critical areas for future research on the
physiological basis of nicotine addiction (Pulvirenti and
Diana, 2001).
Desensitization: neuroprotection and plastic changes
Work from several laboratories show that when ACh, nico-
tine or related agonists are continuously applied nAChRs
become ‘desensitized’ or temporarily inactive (Giniatullin
et al., 2005). Desensitization in addition to protecting cells
from uncontrolled excitation is recently considered as a
form of signal plasticity that might modify synaptic effi-
cacy in various brain regions (Dani et al., 2001; Mansvelder
and McGehee, 2002). In fact, the most obvious neuropro-
tective action of desensitized nAChRs is to inhibit exces-
sive excitation dependent on high permeability to Caþþ of
activated nAChRs. In line with this, mutation at the posi-
tion leucine 247 of the a7 subunit significantly inhibits
desensitization and inserting this mutation into mice can
induce animal death (Wang and Sun, 2005). Recently, a
reasonable working hypothesis has been developed stating
that the phenomena of desensitization beyond simply nico-
tinic receptor inactivation may contribute to the array of
potential effects associated with chronic nicotine exposure.
Numerous studies have demonstrated that chronic nicotine
exposure induces increased numbers of CNS nAChRs both
in vivo in animals and in human smokers, caused by post-
translational mechanisms (Benwell et al., 1988), and in vitro
(Bencherif et al., 1995), although other investigations sup-
port a change not in the number of receptors but in their
state of binding and response to ligands (Vallejo et al.,
2005). This nicotine up-regulation of receptor number is
viewed as responses to desensitization thereby also im-
plying that the desensitized nAChRs may be responsible
for the nicotine’s neuroprotective action (Jonnala and
Buccafusco, 2001). The mechanism may also involve an
enhanced intracellular maturation of the nicotinic receptors
(Sallette et al., 2005). Pretreatment with nicotine for 24 h
has been shown to alleviate the toxic actions of MPTP,
indicating a neuroprotective effect of desensitized nAChRs,
and the neuroprotective action of nicotine in cultured PC12
cells has been suggested to be due to upregulation of a7-
containing nAChRs following their persistent desensitiza-
tion (Jonnala and Buccafusco, 2001). According to this
finding, it has been reported that desensitized a7 nAChRs
have a neuroprotective function through modulating signal
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transduction pathways (Dajas-Bailador et al., 2000; Dani,
2001).
A consistent number of reports suggested that the desen-
sitized nAChRs induced by chronic nicotine may be im-
portant for learning and memory (Lindstrom et al., 1987).
In this context, acute or prolonged chronic nicotine treat-
ment can decrease the threshold for LTP induction in
the hippocampus CA1 and can reverse the age-dependent
decrease in LTP-induction (Fujii and Sumikawa, 2001).
Because a decreased threshold for LTP may be mimicked
by MLA and prevented by a non a7 nAChR blocker, it has
been suggested that a7 nAChR desensitization are mainly
responsible for the effects (Fujii and Sumikawa, 2001).
Furthermore, in view of the negative association between
cigarette smoking and PD or AD, it has also been suggested
that desensitized nAChRs may be responsible for their
neuroprotective actions (Baron, 1996). The use of allosteric
modulator drugs that do not act as agonists on nAChRs,
and therefore cannot generate their widespread desensiti-
zation (Maelicke et al., 2000) may be important tools
for understanding the role of receptor desensitization in
neuroprotection.
Molecular mechanisms mediating neuroprotective
effects of nAChR activation
Nicotine and other nAChR agonists as above described
have neuroprotective=neurotrophic effects in several in vivo
and in vitro models of neuronal death (O’Neill et al., 2002).
Nevertheless, intracellular steps that mediate these effects
of nAChR ligands are not fully solved.
Concerning neuroprotective effects, nAChR activation
evoking Caþþ influx is likely to represent a first step in
the intracellular signalling cascades (Dajas-Bailador et al.,
2000) followed by diverse downstream pathways and pro-
cesses that are subsequently activated. Thus, this activation
of downstream signalling pathways appears necessary for
the prevention of neuronal death. Consistent with this
suggestion, block of Caþþ influx following activation of
a7 nAChR promotes survival of spinal cord motoneurons
from programmed cell death (Messi et al., 1997). In hippo-
campal slices nicotine-induced protection against acute
NMDA damage is mediated by the activation of phosphat-
idylinositol 3-kinase and ERK=MAPK (Ferchmin et al.,
2003) or protein kinase C (Li et al., 1999) and regulation
of Bcl-2 and Bcl-x expression, which may be involved in
prevention of neuronal death (Toborek et al., 2000; Mai et al.,
2003). Other results suggested that nAChR stimulation
induces neuroprotection against glutamate cytotoxicity by
its inhibitory action on NO-formation (Shimohama et al.,
1996). Stimulation of nAChR can also lead to the increased
expression of neurotrophic factors (Belluardo et al., 2000).
Therefore, activation of diverse signalling mechanisms
might subsequently lead to neuroprotection through inhibi-
tion of apoptosis and=or increased expression of neuro-
trophic factors crucial for neuronal maintenance, survival
(Belluardo et al., 2000; Roceri et al., 2001).
Molecular mechanisms mediating neurotrophic
effects of nAChR activation
Regulation of gene expression by synaptic activity is essen-
tial both for normal development in the nervous system and
for long-term components of synaptic plasticity (Dajas-
Bailador et al., 2000). The chain of events connecting
synaptic activity and gene expression is often initiated
by calcium influx (Hardingham et al., 2001), and nAChRs,
and particularly the a7 nAChR, are permeable to Caþþ. In
neurons, nAChRs activation can play a relevant role in Caþþ
signalling not only because of the Caþþ entry through differ-
ent nAChR subtypes, but also because nAChR depolariza-
tion of the plasma membrane can activate voltage operated
calcium channels and may also increase intracellular Caþþ
by inducing Caþþ mobilization from intracellular stores.
The absolute quantity and strategic localization of Caþþ
entry through nAChRs is likely to be relevant for the reg-
ulation of calcium-mediated downstream intracellular
events, including transmitter release, cell excitability, acti-
vation of protein kinases, gene expression, cell differentia-
tion and survival and new protein synthesis, ultimately
leading to changes in synaptic plasticity and neuronal re-
modelling (Dajas-Bailador et al., 2000). Therefore, in addi-
tion to rapid changes in membrane potential, activation of
nAChR can also generate longer-lasting effects in the
receptive neuron, which contribute to the elaboration of
complex intracellular signals that mediate medium-to long-
term events (Role and Berg, 1996).
nAChRs have been implicated in a wide variety of neuro-
trophic events, including learning and memory, which
involve mechanisms for calcium-dependent synaptic regula-
tion (Dajas-Bailador et al., 2000). nAChR agonists activate
mechanisms of synaptic plasticity and long-term enhance-
ment of memory, which involve an increase in the number
and efficiency of synaptic connections between neurons.
Long-lasting cognitive effects of nAChR ligands may be
attributed to the cellular changes that result in synaptic plas-
ticity and LTP is a model of the synaptic plasticity of learn-
ing and memory (Buccafusco et al., 2005).
During the past few decades, the pathways that are in-
volved in synaptic plasticity have been elucidated (Kandel,
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2001), particularly the phenomenon of LTP, which is an
increase in synaptic strength that can persist for extended
periods of time (Bliss and Lomo, 1973). The phases of LTP
correlate with the stages of memory, and impairment of
the mechanisms of LTP leads to memory deficits (Kandel,
2001). In the early phase of LTP, which lasts only hours,
Caþþ dependent second messenger systems modify existing
proteins to enhance neurotransmitter release from presynap-
tic neurons and support short-term memory. Late phases of
LTP require protein synthesis, lasting at least a day, and
require prolonged elevation of the intracellular Caþþ con-
centration. The latter activates a cascade that involves ade-
nylyl cyclase, cAMP and second messengers such as protein
kinase A and mitogen-activated protein kinase (MAPK)
(Impey et al., 1999). In turn, these events may enhance the
activity of transcription factors, e.g. the cAMP response
element-binding protein-1 (CREB-1), which increases the
expression of immediate early genes and stimulates the
synthesis of growth factors and other proteins that potentiate
cell excitability and support the formation of new synaptic
connections. The growth and maintenance of new synaptic
connections enables the persistence of long-term memory
(Kandel, 2001). Much evidence indicate that activation of
nAChRs may initiate a cascade of cellular signals that pro-
duces long-term molecular changes involved in the molecu-
lar mechanisms of memory. Repeated exposure to nAChR
agonists enhances LTP more than a single dose administra-
tion, whereas a persistent activation of nAChRs is not
required for the maintenance phase of LTP. These effects
of nAChR agonists have been characterized most exten-
sively in the hippocampus, where a7 nAChR activation
enhance the probability of LTP and might contribute to the
mechanisms that underlie the effects of nicotine on cognition
(Ji et al., 2001).
nAChR agonists may activate several mechanisms which
may induce long-term changes leading to more complex
neurotrophic response in addition to increased number and
efficiency of synaptic connections between neurons.
Nicotine treatment by increasing permeability of nAChR
to Caþþ can induce PKC activity (Fenster et al., 1999), and
CaþþCaM-dependent protein kinase II, and both effects
can be reversed by nAChR antagonists (Damaj, 2000).
The mitogen-activated protein kinase (MAPK or Erk1=2)
pathway can also be activated by nicotine-dependent in-
creases in Caþþ levels (Cox et al., 1996) or alternatively,
changes in MAPK activity might be regulated by nicotine-
dependent alterations in the levels of fibroblast growth fac-
tors that would activate tyrosine kinase receptor-mediated
pathways (Blum et al., 1996). Similarly, Nicotine-depen-
dent changes in phospholipase C (Pandey, 1996) and PKA
signalling pathways might also be mediated by upstream
effects of nicotine on neurotrophic factors or neurotrans-
mitter release.
Previous studies have demonstrated that nicotine admin-
istration modulated the expression of a variety of genes,
and transcriptional activation (Shim et al., 2000). Exposure
to nAChR agonists elevates the expression of the im-
mediate early genes c-Fos and JunB in several brain areas
(Harlan and Garcia, 1998). The immediate early genes reg-
ulate the transcription of downstream targets that have
diverse roles in signalling, cell growth and cell main-
tenance. Recently, Gene-array technology indicates that
nicotine administration might affect numerous genes, in-
cluding those involved in intracellular signalling, transcrip-
tion, translation, CREB phosphorylation (Gueorguiev et al.,
2004), transmitter receptors, ion channel signalling path-
ways (Sun et al., 2004) and proteins associated with RNA
binding and the plasma membrane (Dunckley and Lukas,
2003). We used Rat Genome U34A Affymetrix GeneChip
arrays to find in the rat parietal cortex new genes respon-
sive to acute intermittent nicotine treatment and linked to
neuroprotection (Belluardo et al., 2005). In this study 25
modified genes were selected and among them five genes
encoding transcription factors were found up regulated
(Nr4a1, Cebpg, Egr-1, Egr-2, JunB). All these transcription
factors show special significance in view of their known
role in regulation of several genes, some of which are
involved in neurotrophic and=or neuroprotective actions.
Among the intracellular events regulated by nAChR acti-
vation, the CREB and ERK=MAPK signalling cascades
have attracted particular attention because their activities
are central to long-term plasticity in the nervous system
(Sweatt, 2001). In fact, activation of ERK=MAPK is re-
quired for the formation of contextual and spatial memories
in mammals (Sweatt, 2001) and nAChR mediate the Caþþ-
dependent activation of ERK=MAPK and sustained phos-
phorylation of CREB in several neuronal models (Chang
and Berg, 2001). Nicotine can alter gene expression in rat
hippocampal neurons, as reflected by activation of the tran-
scription factor CREB and appearance of the immediate
early gene product c-Fos. The process depends on both
CaM and MAP kinases and on calcium release from inter-
nal stores (Hu et al., 2002). These findings in addition to
having directly physiological relevance in learning and
memory, may also have pathological relevance in addiction
(Nestler, 2002). Nicotine dependence, which is mediated
by interaction with nAChR, is likely to involve the mod-
ification of signalling cascades that modulate synaptic plas-
ticity and gene expression, as proposed for other drugs of
abuse (Nestler, 2001; Dani et al., 2001). Although there are
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few reports on the contributions of signalling pathways in
models of nicotine addiction, several studies have focused
on the modulation of CREB following chronic treatment with
nicotine. CREB activation is required for nicotine reward
(Walters et al., 2005) and nicotine withdrawal significantly
reduced the concentrations of CREB and phosphorylated
CREB in rat cortex and amygdala (Pandey et al., 2001). Phos-
phorylated CREB appears also to be decreased in the nucleus
accumbens in mice following chronic consumption of nico-
tine in their drinking water (Brunzell et al., 2003). Overall,
these results support a role for ERK and CREB activity
in neural plasticity associated with nicotine dependence.
nAChRs activation is involved on neurotrophic
factor gene expression
The mechanisms by which nicotinic signalling may regu-
lates gene expression are poorly understood, and it is not
known how such mechanisms interact with other calcium
dependent pathways controlling transcription. Therefore, a
comprehensive survey of the gene-based molecular mech-
anisms that underlie nicotine effects is yet to be performed.
During the last years we have begun a study aimed to
identify genes encoding neurotrophic factors targeted by
nAChR activation and to elucidate the signalling pathways
through which nAChR regulate their expression.
Several neuronal populations within the adult CNS re-
quire the presence of neurotrophic factors to maintain neu-
ronal function (Sofroniew et al., 1990) and survival (Barde,
1989). Long-term changes in synaptic plasticity are asso-
ciated with neurotrophic factors (Pang et al., 2004) and the
reduction in neurotrophic factor expression may result in
the neuronal atrophy seen in normal ageing or the neuronal
loss observed in neurodegenerative disorders such as AD
and PD (Connor and Dragunow, 1998). Therefore a neuro-
trophic factor gene regulation by nAChR signalling has
been also taken into consideration as a possible mecha-
nism involved in neuroprotective=neurotrophic effects by
nAChR activation.
We have analysed the effects of acute intermittent nico-
tine treatment on FGF-2 expression and the results obtained
(Belluardo et al., 1998) showed that treatment with acute
intermittent nicotine (four i.p. injections at intervals of
30 min; 1 mg=kg), or with other nicotinic agonists such
as epibatidine and ABT-594, lead to a substantial upregula-
tion of FGF-2 mRNA and protein levels in the cerebral
cortex, the hippocampal formation, the striatum and the
ventral midbrain. An extension of this model to the study
of aged rats (24 months old) showed that the nicotine-
induced increases of FGF-2 mRNA levels is preserved
during aging (Belluardo et al., 1999a, 2000). In cultured
chromaffin cells from bovine adrenal medullae stimulation
of nAChR increases FGF-2 gene expression (Stachowiak
et al., 1994). This nAChR-mediated increase in expression
of FGF-2 gene was mediated by adenylate cyclase or pro-
tein kinase C and dependent on nuclear interaction of trans-
activating factors with a novel cis-acting element (Moffett
et al., 1998). In order to elucidate the signalling pathways
through which nAChR regulate FGF-2 expression we focus
on transcription factors identifying a potential role of
CREB. We could verify the presence in the promoter of
the FGF-2 gene a CRE-site which is able to bind CREB
(unpublished data). This involvement of CREB is also sup-
ported by the ability of acute nicotine treatment to induce
phosphorylation of CREB, without a change in CREB
levels, and to increase activation of ERK-1 (unpublished
data), which suggests an involvement of Ras=mitogen-
activated protein kinase (MAPK) pathways.
This regulation of FGF-2 gene in turn can exert neuro-
trophic functions involving neuronal survival, trophism and
plasticity. FGF-2 exerts its pleiotropic effect through spe-
cific high- and low-affinity receptors named FGFR-1-4
(Belluardo et al., 1997). FGF-2 has been implicated to be
the potent neurotrophic factor that promotes mitosis and
differentiation of neuroblasts (Mayer et al., 1993), and neu-
ronal survival and neurite extension (Ferrari et al., 1989)
and protects cultured central neurons from different insults
(Cheng and Mattson, 1991). An in vivo protective role for
FGF-2 has been indicated by studies showing that FGF-2
can support the survival of cholinergic basal forebrain neu-
rons following fimbria transaction (Anderson et al., 1988),
dopaminergic neurons following MPTP toxicity (Chadi
et al., 1993) and hippocampal neurons following cerebral
ischemia (Nakata et al., 1993) or hippocampal damage
after excytotoxic injury (Mattson et al., 1989). Endogenous
expression of FGF-2 blocked by neutralizing antibodies
following unilateral suction lesions of the motor cortex
retards recovery from injury in rats (Rowntree and Kolb,
1997). A loss of FGF-2 in the substantia nigra in PD has
been reported (Tooyama et al., 1993). Transgenic mice
lacking FGF-2 showed a reduction in the neuronal density
in the motor cortex, with layer V more greatly affected
(Ortega et al., 1998), suggesting that FGF-2 controls mi-
gration, differentiation and survival especially of cortical
neurons (Dono et al., 1998). Recently FGF-2 has been im-
plicated in neurogenesis in adult rat brain (Kuhn et al.,
1997). In this context we revealed in the neuroepithelium
of the subventricular zone of the lateral ventricle in the adult
rat brain the existence of a trophic mechanism mediated by
FGF-2 and its receptor and regulated by nAChR, activation
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of which by acute intermittent nicotine treatment enhances
neuronal precursor proliferation (Mudo’ et al., 2005) Other
pieces of evidence that nAChRs may play a direct role in the
regulation of neurogenesis come from the reported decline
of hippocampal cell proliferation in mice lacking the b2
subunit (Harrist et al., 2004), and a decrease of neurogenesis
in the adult hippocampal formation following chronic nico-
tine self-administration (Abrous et al., 2002). These findings
suggest the possibility of in vivo regulation of neurogenesis
in the adult brain by nicotine agonists and may help to
develop treatment stimulating neurogenesis with important
therapeutic implication.
Several reports have showed that other neurotrophic
factors may be under regulation of nAChR activation.
Intra-hippocampal administration of nicotine increases
transiently NGF in the CA1 and dentate gyrus of the hip-
pocampus and PC12 neuronal cells exposed to nicotine
increase NGF receptor expression (Jonnala et al., 2002).
Acute intermittent nicotine treatment increase levels of
BDNF in the rat striatum (Maggio et al., 1998), although
other reports in similar experimental models have indicated
as unchanged the BDNF levels (Belluardo et al., 1999a).
NGF itself enhances ACh release (Lapchak et al., 1994),
increases mRNA that encodes nAChR subunits (Henderson
et al., 1994) and promotes sprouting of ACh-containing
fibers in the septum (Heisenberg et al., 1994). Nevertheless,
in contrast to NGF, which is expressed only in restricted
regions of brain and does not give account for the large
effects of nicotine in several brain regions, FGF-2 is widely
distributed in the adult CNS both in neuronal and non
neuronal cells (Fuxe et al., 1996) and the potent and wide-
spread activation of FGF-2 in several brain regions follow-
ing nicotine treatment suggested that the cholinergic
activation of the FGF-2 gene via nAChR may be better
suited to participate in the plasticity changes and improved
neuronal survival in the brain found after nicotine agonist
treatment. Therefore, this FGF-2 nicotine activation sup-
ports the suggestion that the previously observed neuropro-
tective effects of nicotine and the potential beneficial
effects of nicotine agonists in the treatment of AD and
PD, may at least in part involve an activation of the neu-
ronal and glial FGF-2 signalling.
Conclusions
Although the large amount of data acquired in the last years
have added new important insight in our understanding the
molecular mechanisms that underlie nicotine effects, more
work is needed to establish the mechanisms involved in
any nicotinic receptor activation effects, from cognition-
enhancing effects to smoking behaviour, and to determine
more precisely the therapeutic objectives in potential nic-
otinic drug treatment of neurodegenerative diseases. In addi-
tion, it will be also important to determine how the diverse
nAChR subtypes are integrated in such actions and the
impact of their changes for pathology, and to define whether
neuroprotective=neurotrophic and cognitive enhancements
are mediated via acute activation, repetitive activation, or
more chronic inactivation of nAChR function or by some
combination of these actions. Such knowledge is important
for the development of targeted drug therapies acting on
nAChRs to delay the onset and progression of chronic age
related brain neurodegenerative pathologies, as seen in PD
and AD, leading to improvement of cognitive abilities.
References
Abrous DN, Adriani W, Montaron MF, Aurousseau C, Rougon G, Le MM,
Piazza PV (2002) Nicotine self-administration impairs hippocampal
plasticity. J Neurosci 22: 3656–3662
Allen TB, McEvoy JP (2002) Galantamine for treatment-resistant schizo-
phrenia. Am J Psychiatry 159: 1244–1245
Anderson KJ, Dam D, Lee S, Cotman CW (1988) Basic fibroblast growth
factor prevents death of lesioned cholinergic neurons in vivo. Nature
332: 360–361
Andersson K, Fuxe K, Agnati LF (1981) Effects of single injections of
nicotine on the ascending dopamine pathways in the rat. Evidence for
increases of dopamine turnover in the mesostriatal and mesolimbic
dopamine neurons. Acta Physiol Scand 112: 345–347
Arendash GW, Sengstock GJ, Sanberg PR, Kem WR (1995) Improved
learning and memory in aged rats with chronic administration of the
nicotinic receptor agonist GTS-21. Brain Res 674: 252–259
Banerjee C, Nyengaard JR, Wevers A, de Vos RA, Jansen Steur EN,
Lindstrom J, Pilz K, Nowacki S, Bloch W, Schroder H (2000) Cellular
expression of alpha7 nicotinic acetylcholine receptor protein in the
temporal cortex in Alzheimer’s and Parkinson’s disease – a stereo-
logical approach. Neurobiol Dis 7: 666–672
Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D,
Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD,
Williams M, Arneric SP (1998) Broad-spectrum, non-opioid analgesic
activity by selective modulation of neuronal nicotinic acetylcholine
receptors. Science 279: 77–81
Barde YA (1989) Trophic factors and neuronal survival. Neuron 2:
1525–1534
Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL (2000)
Chronic treatment of old rats with donepezil or galantamine: effects on
memory, hippocampal plasticity and nicotinic receptors. Neuroscience
99: 17–23
Baron JA (1986) Cigarette smoking and Parkinson’s disease. Neurology 36:
1490–1496
Baron JA (1996) Beneficial effects of nicotine and cigarette smoking: the
real, the possible and the spurious. Br Med Bull 52: 58–73
Belluardo N, Blum M, Mudo G, Andbjer B, Fuxe K (1998) Acute
intermittent nicotine treatment produces regional increases of basic
fibroblast growth factor messenger RNA and protein in the tel- and
diencephalon of the rat. Neuroscience 83: 723–740
Belluardo N, Mudo G, Blum M, Cheng Q, Caniglia G, Dell’Albani P, Fuxe
K (1999a) The nicotinic acetylcholine receptor agonist (þ=)-epiba-
tidine increases FGF-2 mRNA and protein levels in the rat brain. Brain
Res Mol Brain Res 74: 98–110
Nicotinic receptor agonists as neuroprotective=neurotrophic drugs 143
Belluardo N, Mudo G, Blum M, Fuxe K (2000) Central nicotinic re-
ceptors, neurotrophic factors and neuroprotection. Behav Brain Res
113: 21–34
Belluardo N, Mudo G, Caniglia G, Cheng Q, Blum M, Fuxe K (1999b) The
nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2
expression in various rat brain regions. Neuroreport 10: 3909–3913
Belluardo N, Olsson PA, Mudo’ G, Sommer WH, Amato G, Fuxe K (2005)
Transcription factor gene expression profiling after acute intermittent
nicotine treatment in the rat cerebral cortex. Neuroscience 133: 787–796
Belluardo N, Wu G, Mudo G, Hansson AC, Pettersson R, Fuxe K (1997)
Comparative localization of fibroblast growth factor receptor-1, -2, and
-3 mRNAs in the rat brain: in situ hybridization analysis. J Comp
Neurol 379: 226–246
Bencherif M, Fowler K, Lukas RJ, Lippiello PM (1995) Mechanisms of up-
regulation of neuronal nicotinic acetylcholine receptors in clonal cell
lines and primary cultures of fetal rat brain. J Pharmacol Exp Ther 275:
987–994
Benwell ME, Balfour DJ, Anderson JM (1988) Evidence that tobacco
smoking increases the density of (–)-[3H]nicotine binding sites in
human brain. J Neurochem 50: 1243–1247
Bliss TV, Lomo T (1973) Long-lasting potentiation of synaptic transmis-
sion in the dentate area of the anaesthetized rabbit following stimula-
tion of the perforant path. J Physiol 232: 331–356
Blum M, Wu G, Mudo G, Belluardo N, Andersson K, Agnati LF, Fuxe K
(1996) Chronic continuous infusion of (–)nicotine reduces basic
fibroblast growth factor messenger RNA levels in the ventral midbrain
of the intact but not of the 6-hydroxydopamine-lesioned rat. Neu-
roscience 70: 169–177
Bonci A, Malenka RC (1999) Properties and plasticity of excitatory synapses
on dopaminergic and GABAergic cells in the ventral tegmental area.
J Neurosci 19: 3723–3730
Broide RS, Leslie FM (1999) The alpha7 nicotinic acetylcholine receptor in
neuronal plasticity. Mol Neurobiol 20: 1–16
Brunzell DH, Russell DS, Picciotto MR (2003) In vivo nicotine treatment
regulates mesocorticolimbic CREB and ERK signaling in C57Bl=6J
mice. J Neurochem 84: 1431–1441
Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM (2005) Long-
lasting cognitive improvement with nicotinic receptor agonists: mech-
anisms of pharmacokinetic-pharmacodynamic discordance. Trends
Pharmacol Sci 26: 352–360
Burghaus L, Schutz U, Krempel U, Lindstrom J, Schroder H (2003) Loss of
nicotinic acetylcholine receptor subunits alpha4 and alpha7 in the
cerebral cortex of Parkinson patients. Parkinsonism Relat Disord 9:
243–246
Chadi G, Moller A, Rosen L, Janson AM, Agnati LA, Goldstein M, Ogren
SO, Pettersson RF, Fuxe K (1993) Protective actions of human
recombinant basic fibroblast growth factor on MPTP-lesioned nigros-
triatal dopamine neurons after intraventricular infusion. Exp Brain Res
97: 145–158
Chang KT, Berg DK (2001) Voltage-gated channels block nicotinic reg-
ulation of CREB phosphorylation and gene expression in neurons.
Neuron 32: 855–865
Changeux JP, Bertrand D, Corringer PJ, Dehaene S, Edelstein S, Lena C, Le
NN, Marubio L, Picciotto M, Zoli M (1998) Brain nicotinic receptors:
structure and regulation, role in learning and reinforcement. Brain Res
Rev 26: 198–216
Cheng B, Mattson MP (1991) NGF and bFGF protect rat hippocampal and
human cortical neurons against hypoglycemic damage by stabilizing
calcium homeostasis. Neuron 7: 1031–1041
Connor B, Dragunow M (1998) The role of neuronal growth factors in
neurodegenerative disorders of the human brain. Brain Res Rev 27:
1–39
Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E (2001)
Nicotinic receptor abnormalities in Alzheimer’s disease. Biol Psychia-
try 49: 175–184
Couturier S, Bertrand D, Matter JM, Hernandez MC, Bertrand S, Millar N,
Valera S, Barkas T, Ballivet M (1990) A neuronal nicotinic acetylcholine
receptor subunit (alpha 7) is developmentally regulated and forms a
homo-oligomeric channel blocked by alpha-BTX. Neuron 5: 847–856
Cox ME, Ely CM, Catling AD, Weber MJ, Parsons SJ (1996) Tyrosine
kinases are required for catecholamine secretion and mitogen-activated
protein kinase activation in bovine adrenal chromaffin cells. J Neu-
rochem 66: 1103–1112
Dajas-Bailador FA, Lima PA, Wonnacott S (2000) The alpha7 nicotinic
acetylcholine receptor subtype mediates nicotine protection against
NMDA excitotoxicity in primary hippocampal cultures through a
Ca(2þ) dependent mechanism. Neuropharmacology 39: 2799–2807
Damaj MI (2000) The involvement of spinal Ca(2þ)=calmodulin-protein
kinase II in nicotine-induced antinociception in mice. Eur J Pharmacol
404: 103–110
Dani JA (2001) Overview of nicotinic receptors and their roles in the central
nervous system. Biol Psychiatry 49: 166–174
Dani JA, Ji D, Zhou FM (2001) Synaptic plasticity and nicotine addiction.
Neuron 31: 349–352
De La Garza VW (2003) Pharmacologic treatment of Alzheimer’s disease:
an update. Am Fam Physician 68: 1365–1372
Decker MW, Brioni JD, Bannon AW, Arneric SP (1995) Diversity of
neuronal nicotinic acetylcholine receptors: lessons from behavior
and implications for CNS therapeutics. Life Sci 56: 545–570
Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz
JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT (1994a) (S)-3-
methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cho-
linergic ligand with cognition-enhancing and anxiolytic activities: II.
In vivo characterization. J Pharmacol Exp Ther 270: 319–328
Decker MW, Curzon P, Brioni JD, Arneric SP (1994b) Effects of ABT-418,
a novel cholinergic channel ligand, on place learning in septal-lesioned
rats. Eur J Pharmacol 261: 217–222
Deutsch SI, Rosse RB, Schwartz BL, Weizman A, Chilton M, Arnold DS,
Mastropaolo J (2005) Therapeutic implications of a selective alpha7
nicotinic receptor abnormality in schizophrenia. Isr. J Psychiatry Relat
Sci 42: 33–44
DiFranza JR, Wellman RJ (2003) Preventing cancer by controlling youth
tobacco use. Semin Oncol Nurs 19: 261–267
Dono R, Texido G, Dussel R, Ehmke H, Zeller R (1998) Impaired cerebral
cortex development and blood pressure regulation in FGF-2-deficient
mice. EMBO J 17: 4213–4225
Dunckley T, Lukas RJ (2003) Nicotine modulates the expression of a
diverse set of genes in the neuronal SH-SY5Y cell line. J Biol Chem
278: 15633–15640
Fenster CP, Beckman ML, Parker JC, Sheffield EB, Whitworth TL, Quick
MW, Lester RA (1999) Regulation of alpha4beta2 nicotinic receptor
desensitization by calcium and protein kinase C. Mol Pharmacol 55:
432–443
Ferchmin PA, Perez D, Eterovic VA, de VJ (2003) Nicotinic receptors
differentially regulate N-methyl-D-aspartate damage in acute hippo-
campal slices. J Pharmacol Exp Ther 305: 1071–1078
Ferrari G, Minozzi MC, Toffano G, Leon A, Skaper SD (1989) Basic
fibroblast growth factor promotes the survival and development of
mesencephalic neurons in culture. Dev Biol 133: 140–147
Forgacs PB, Bodis-Wollner I (2004) Nicotinic receptors and cognition in
Parkinson’s Disease: the importance of neuronal synchrony. J Neural
Transm 111: 1317–1331
Fratiglioni L, Wang HX (2000) Smoking and Parkinson’s and Alzheimer’s
disease: review of the epidemiological studies. Behav Brain Res 113:
117–120
Freedman R (2005) The choice of antipsychotic drugs for schizophrenia. N
Engl J Med 353: 1286–1288
Fujii S, Sumikawa K (2001) Acute and chronic nicotine exposure reverse
age-related declines in the induction of long-term potentiation in the rat
hippocampus. Brain Res 894: 347–353
144 G. Mudo et al.
Fuxe K, Andersson K, Eneroth P, Harfstrand A, Agnati LF (1989) Neu-
roendocrine actions of nicotine and of exposure to cigarette smoke:
medical implications. Psychoneuroendocrinology 14: 19–41
Fuxe K, Andersson K, Harfstrand A, Agnati LF (1986) Increases in
dopamine utilization in certain limbic dopamine terminal populations
after a short period of intermittent exposure of male rats to cigarette
smoke. J Neural Transm 67: 15–29
Fuxe K, Janson AM, Jansson A, Andersson K, Eneroth P, Agnati LF (1990)
Chronic nicotine treatment increases dopamine levels and reduces
dopamine utilization in substantia nigra and in surviving forebrain
dopamine nerve terminal systems after a partial di-mesencephalic
hemitransection. Naunyn Schmiedebergs Arch Pharmacol 341: 171–181
Fuxe K, Tinner B, Zoli M, Pettersson RF, Baird A, Biagini G, Chadi G,
Agnati LF (1996) Computer-assisted mapping of basic fibroblast
growth factor immunoreactive nerve cell populations in the rat brain.
J Chem Neuroanat 11: 13–35
Geerts H (2005) Indicators of neuroprotection with galantamine. Brain Res
Bull 64: 519–524
Giniatullin R, Nistri A, Yakel JL (2005) Desensitization of nicotinic
ACh receptors: shaping cholinergic signaling. Trends Neurosci 28:
371–378
Gioanni Y, Rougeot C, Clarke PB, Lepouse C, Thierry AM, Vidal C (1999)
Nicotinic receptors in the rat prefrontal cortex: increase in glutamate
release and facilitation of mediodorsal thalamo-cortical transmission.
Eur J Neurosci 11: 18–30
Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to
pathology. Prog Neurobiol 74: 363–396
Gould TJ, Stephen HJ (2003) Nicotine enhances contextual fear condi-
tioning in C57BL=6J mice at 1 and 7 days post-training. Neurobiol
Learn Mem 80: 147–157
Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA (1996) Hippo-
campal synaptic transmission enhanced by low concentrations of
nicotine. Nature 383: 713–716
Groenewegen HJ, Uylings HB (2000) The prefrontal cortex and the in-
tegration of sensory, limbic and autonomic information. Prog Brain
Res 126: 3–28
Gueorguiev VD, Frenz CM, Ronald KM, Sabban EL (2004) Nicotine and
epibatidine triggered prolonged rise in calcium and TH gene transcrip-
tion in PC12 cells. Eur J Pharmacol 506: 37–46
Gueorguiev VD, Zeman RJ, Meyer EM, Sabban EL (2000) Involvement of
alpha7 nicotinic acetylcholine receptors in activation of tyrosine hy-
droxylase and dopamine beta-hydroxylase gene expression in PC12
cells. J Neurochem 75: 1997–2005
Hardingham GE, Arnold FJ, Bading H (2001) Nuclear calcium signaling
controls CREB-mediated gene expression triggered by synaptic activ-
ity. Nat Neurosci 4: 261–267
Harlan RE, Garcia MM (1998) Drugs of abuse and immediate-early genes
in the forebrain. Mol Neurobiol 16: 221–267
Harrist A, Beech RD, King SL, Zanardi A, Cleary MA, Caldarone BJ, Eisch
A, Zoli M, Picciotto MR (2004) Alteration of hippocampal cell
proliferation in mice lacking the beta 2 subunit of the neuronal
nicotinic acetylcholine receptor. Synapse 54: 200–206
Heisenberg CP, Cooper JD, Berke J, Sofroniew MV (1994) NMDA
potentiates NGF-induced sprouting of septal cholinergic fibres. Neu-
roreport 5: 413–416
Henderson LP, Gdovin MJ, Liu C, Gardner PD, Maue RA (1994) Nerve
growth factor increases nicotinic ACh receptor gene expression and
current density in wild-type and protein kinase A-deficient PC12 cells.
J Neurosci 14: 1153–1163
Hu M, Liu QS, Chang KT, Berg DK (2002) Nicotinic regulation of CREB
activation in hippocampal neurons by glutamatergic and nonglutama-
tergic pathways. Mol Cell Neurosci 21: 616–625
Huerta PT, Lisman JE (1993) Heightened synaptic plasticity of hippocam-
pal CA1 neurons during a cholinergically induced rhythmic state.
Nature 364: 723–725
Impey S, Obrietan K, Storm DR (1999) Making new connections: role
of ERK=MAP kinase signaling in neuronal plasticity. Neuron 23:
11–14
Janson AM, Fuxe K, Agnati LF, Jansson A, Bjelke B, Sundstrom E,
Andersson K, Harfstrand A, Goldstein M, Owman C (1989) Protective
effects of chronic nicotine treatment on lesioned nigrostriatal dopa-
mine neurons in the male rat. Prog Brain Res 79: 257–265
Janson AM, Fuxe K, Agnati LF, Kitayama I, Harfstrand A, Andersson K,
Goldstein M (1988a) Chronic nicotine treatment counteracts the
disappearance of tyrosine-hydroxylase-immunoreactive nerve cell
bodies, dendrites and terminals in the mesostriatal dopamine system of
the male rat after partial hemitransection. Brain Res 455: 332–345
Janson AM, Fuxe K, Sundstrom E, Agnati LF, Goldstein M (1988b) Chronic
nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-
tetrahydropyridine-induced degeneration of nigrostriatal dopamine neu-
rons in the black mouse. Acta Physiol Scand 132: 589–591
Janson AM, Moller A (1993) Chronic nicotine treatment counteracts nigral
cell loss induced by a partial mesodiencephalic hemitransection: an
analysis of the total number and mean volume of neurons and glia in
substantia nigra of the male rat. Neuroscience 57: 931–941
Jeyarasasingam G, Tompkins L, Quik M (2002) Stimulation of non-alpha7
nicotinic receptors partially protects dopaminergic neurons from 1-
methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience
109: 275–285
Ji D, Dani JA (2000) Inhibition and disinhibition of pyramidal neurons by
activation of nicotinic receptors on hippocampal interneurons. J Neu-
rophysiol 83: 2682–2690
Ji D, Lape R, Dani JA (2001) Timing and location of nicotinic activity
enhances or depresses hippocampal synaptic plasticity. Neuron 31:
131–141
Jonnala RR, Buccafusco JJ (2001) Relationship between the increased cell
surface alpha7 nicotinic receptor expression and neuroprotection
induced by several nicotinic receptor agonists. J Neurosci Res 66:
565–572
Jonnala RR, Terry AV Jr, Buccafusco JJ (2002) Nicotine increases the
expression of high affinity nerve growth factor receptors in both in vitro
and in vivo. Life Sci 70: 1543–1554
Kandel ER (2001) The molecular biology of memory storage: a dialogue
between genes and synapses. Science 294: 1030–1038
Kaneko S, Maeda T, Kume T, Kochiyama H, Akaike A, Shimohama S,
Kimura J (1997) Nicotine protects cultured cortical neurons against
glutamate-induced cytotoxicity via alpha7-neuronal receptors and
neuronal CNS receptors. Brain Res 765: 135–140
Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of
nicotine on Parkinson’s disease. Brain Cogn 43: 274–282
Kem WR (2000) The brain alpha7 nicotinic receptor may be an important
therapeutic target for the treatment of Alzheimer’s disease: studies
with DMXBA (GTS-21). Behav Brain Res 113: 169–181
Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H,
Kume T, Akaike A (2001) alpha 7 nicotinic receptor transduces signals
to phosphatidylinositol 3-kinase to block A beta-amyloid-induced
neurotoxicity. J Biol Chem 276: 13541–13546
Kita T, Okamoto M, Nakashima T (1992) Nicotine-induced sensitization to
ambulatory stimulant effect produced by daily administration into the
ventral tegmental area and the nucleus accumbens in rats. Life Sci 50:
583–590
Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H,
Nakazato M, Okamura N, Stevens KE, Freedman R, Iyo M (2005)
Tropisetron improves deficits in auditory P50 suppression in schizo-
phrenia. Schizophr Res 76: 67–72
Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH (1997) Epidermal
growth factor and fibroblast growth factor-2 have different effects on
neural progenitors in the adult rat brain. J Neurosci 17: 5820–5829
Lapchak PA, Araujo DM, Hefti F (1994) Effects of chronic nerve growth
factor treatment on hippocampal [3H]cytisine=nicotinic binding sites
Nicotinic receptor agonists as neuroprotective=neurotrophic drugs 145
and presynaptic nicotinic receptor function following fimbrial transec-
tions. Neuroscience 60: 293–298
Lawrence NS, Ross TJ, Stein EA (2002) Cognitive mechanisms of nicotine
on visual attention. Neuron 36: 539–548
Le Novere N, Changeux JP (1995) Molecular evolution of the nicotinic
acetylcholine receptor: an example of multigene family in excitable
cells. J Mol Evol 40: 155–172
Le Novere N, Corringer PJ, Changeux JP (2002) The diversity of subunit
composition in nAChRs: evolutionary origins, physiologic and phar-
macologic consequences. J Neurobiol 53: 447–456
Lena C, Changeux JP (1998) Allosteric nicotinic receptors, human pathol-
ogies. J Physiol Paris 92: 63–74
Levin ED, Bettegowda C, Blosser J, Gordon J (1999) AR-R17779, and
alpha7 nicotinic agonist, improves learning and memory in rats. Behav
Pharmacol 10: 675–680
Levin ED, Bradley A, Addy N, Sigurani N (2002) Hippocampal alpha 7 and
alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience
109: 757–765
Levin ED, Christopher NC, Briggs SJ, Rose JE (1993) Chronic nicotine
reverses working memory deficits caused by lesions of the fimbria or
medial basalocortical projection. Brain Res Cogn Brain Res 1: 137–143
Levin ED, Rezvani AH (2000) Development of nicotinic drug therapy for
cognitive disorders. Eur J Pharmacol 393: 141–146
Levin ED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive
function in animals. Psychopharmacology (Berl) 138: 217–230
Li Y, Papke RL, He YJ, Millard WJ, Meyer EM (1999) Characterization of
the neuroprotective and toxic effects of alpha7 nicotinic receptor
activation in PC12 cells. Brain Res 830: 218–225
Lichtensteiger W, Hefti F, Felix D, Huwyler T, Melamed E, Schlumpf M
(1982) Stimulation of nigrostriatal dopamine neurones by nicotine.
Neuropharmacology 21: 963–968
Lindstrom J, Schoepfer R, Whiting P (1987) Molecular studies of the neuronal
nicotinic acetylcholine receptor family. Mol Neurobiol 1: 281–337
Lipska BK (2004) Using animal models to test a neurodevelopmental
hypothesis of schizophrenia. J Psychiatry Neurosci 29: 282–286
Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J,
Albuquerque EX, Zerlin M (2001) Allosteric sensitization of nicotinic
receptors by galantamine, a new treatment strategy for Alzheimer’s
disease. Biol Psychiatry 49: 279–288
Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque
EX (2000) Allosterically potentiating ligands of nicotinic receptors
as a treatment strategy for Alzheimer’s disease. Behav Brain Res
113: 199–206
Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, Racagni G,
Corsini GU (1998) Nicotine prevents experimental parkinsonism in
rodents and induces striatal increase of neurotrophic factors. J Neu-
rochem 71: 2439–2446
Mai H, May WS, Gao F, Jin Z, Deng X (2003) A functional role for nicotine
in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem
278: 1886–1891
Mansvelder HD, McGehee DS (2000) Long-term potentiation of excitatory
inputs to brain reward areas by nicotine. Neuron 27: 349–357
Mansvelder HD, McGehee DS (2002) Cellular and synaptic mechanisms of
nicotine addiction. J Neurobiol 53: 606–617
Martin LF, Kem WR, Freedman R (2004) Alpha-7 nicotinic receptor
agonists: potential new candidates for the treatment of schizophrenia.
Psychopharmacology (Berl) 174: 54–64
Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A,
Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK (1999) Alpha4
but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are
lost from the temporal cortex in Alzheimer’s disease. J Neurochem 73:
1635–1640
Mattson MP, Murrain M, Guthrie PB, Kater SB (1989) Fibroblast growth
factor and glutamate: opposing roles in the generation and degenera-
tion of hippocampal neuroarchitecture. J Neurosci 9: 3728–3740
Mayer E, Dunnett SB, Fawcett JW (1993) Mitogenic effect of basic
fibroblast growth factor on embryonic ventral mesencephalic dopami-
nergic neurone precursors. Brain Res Dev Brain Res 72: 253–258
Messi ML, Renganathan M, Grigorenko E, Delbono O (1997) Activation of
alpha7 nicotinic acetylcholine receptor promotes survival of spinal
cord motoneurons. FEBS Lett 411: 32–38
Mexal S, Frank M, Berger R, Adams CE, Ross RG, Freedman R, Leonard S
(2005) Differential modulation of gene expression in the NMDA
postsynaptic density of schizophrenic and control smokers. Brain
Res Mol Brain Res 139: 317–332
Moffett J, Kratz E, Stachowiak MK (1998) Increased tyrosine phosphor-
ylation and novel cis-acting element mediate activation of the fibro-
blast growth factor-2 (FGF-2) gene by nicotinic acetylcholine receptor.
New mechanism for trans-synaptic regulation of cellular development
and plasticity. Brain Res Mol Brain Res 55: 293–305
Mudo G, Mauro A, Trentuno D, Curcio E, Belluardo N, Fuxe K (2005)
Acute intermittent nicotine treatment enhances proliferation of neu-
ronal precursor cells in the subventricular zone (svz) of adult rat brain.
National Congress of the Italian Society for Neuroscience and Joint
Italian-Swedish Neuroscience Meeting, 1–4 Ottobre, Lacco Ameno,
Ischia (Naples): P 19_02
Nakata N, Kato H, Kogure K (1993) Protective effects of basic fibroblast
growth factor against hippocampal neuronal damage following cere-
bral ischemia in the gerbil. Brain Res 605: 354–356
Nanri M, Yamamoto J, Miyake H, Watanabe H (1998) Protective effect of
GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death
induced by ischemia in gerbils. Jpn J Pharmacol 76: 23–29
Navarro HA, Seidler FJ, Eylers JP, Baker FE, Dobbins SS, Lappi SE,
Slotkin TA (1989) Effects of prenatal nicotine exposure on develop-
ment of central and peripheral cholinergic neurotransmitter systems.
Evidence for cholinergic trophic influences in developing brain. J
Pharmacol Exp Ther 251: 894–900
Nestler EJ (2001) Molecular basis of long-term plasticity underlying
addiction. Nat Rev Neurosci 2: 119–128
Nestler EJ (2002) Common molecular and cellular substrates of addiction
and memory. Neurobiol Learn Mem 78: 637–647
Newhouse PA, Potter A, Kelton M, Corwin J (2001) Nicotinic treatment of
Alzheimer’s disease. Biol Psychiatry 49: 268–278
Newhouse PA, Potter A, Singh A (2004) Effects of nicotinic stimulation on
cognitive performance. Curr Opin Pharmacol 4: 36–46
Nomikos GG, Schilstrom B, Hildebrand BE, Panagis G, Grenhoff J,
Svensson TH (2000) Role of alpha7 nicotinic receptors in nicotine
dependence and implications for psychiatric illness. Behav Brain Res
113: 97–103
O’Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S (2002) The role
of neuronal nicotinic acetylcholine receptors in acute and chronic
neurodegeneration. Curr Drug Targets CNS Neurol Disord 1:
399–411
Ortega S, Ittmann M, Tsang SH, Ehrlich M, Basilico C (1998) Neuronal
defects and delayed wound healing in mice lacking fibroblast growth
factor 2. Proc Natl Acad Sci USA 95: 5672–5677
Pandey SC (1996) Effects of chronic nicotine treatment on the expression of
phospholipase C isozymes and the alpha subunit of Gq=11 protein in
the rat brain. Neurosci Lett 212: 127–130
Pandey SC, Roy A, Xu T, Mittal N (2001) Effects of protracted nicotine
exposure and withdrawal on the expression and phosphorylation of
the CREB gene transcription factor in rat brain. J Neurochem 77:
943–952
Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung
WH, Hempstead BL, Lu B (2004) Cleavage of proBDNF by tPA=
plasmin is essential for long-term hippocampal plasticity. Science 306:
487–491
Perry DC, vila-Garcia MI, Stockmeier CA, Kellar KJ (1999) Increased
nicotinic receptors in brains from smokers: membrane binding and
autoradiography studies. J Pharmacol Exp Ther 289: 1545–1552
146 G. Mudo et al.
Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King
SL (2001) Neuronal nicotinic acetylcholine receptor subunit knockout
mice: physiological and behavioral phenotypes and possible clinical
implications. Pharmacol Ther 92: 89–108
Pugh PC, Berg DK (1994) Neuronal acetylcholine receptors that bind
alpha-bungarotoxin mediate neurite retraction in a calcium-dependent
manner. J Neurosci 14: 889–896
Pulvirenti L, Diana M (2001) Drug dependence as a disorder of neural
plasticity: focus on dopamine and glutamate. Rev Neurosci 12: 141–158
Quik M (2004) Smoking, nicotine and Parkinson’s disease. Trends Neurosci
27: 561–568
Ripoll N, Bronnec M, Bourin M (2004) Nicotinic receptors and schizo-
phrenia. Curr Med Res Opin 20: 1057–1074
Roceri M, Molteni R, Fumagalli F, Racagni G, Gennarelli M, Corsini G,
Maggio R, Riva M (2001) Stimulatory role of dopamine on fibro-
blast growth factor-2 expression in rat striatum. J Neurochem 76:
990–997
Role LW, Berg DK (1996) Nicotinic receptors in the development and
modulation of CNS synapses. Neuron 16: 1077–1085
Rowntree S, Kolb B (1997) Blockade of basic fibroblast growth factor
retards recovery from motor cortex injury in rats. Eur J Neurosci 9:
2432–2441
Ryan RE, Ross SA, Drago J, Loiacono RE (2001) Dose-related neuropro-
tective effects of chronic nicotine in 6-hydroxydopamine treated rats,
and loss of neuroprotection in alpha4 nicotinic receptor subunit
knockout mice. Br J Pharmacol 132: 1650–1656
Sacco KA, Bannon KL, George TP (2004) Nicotinic receptor mechanisms
and cognition in normal states and neuropsychiatric disorders. J
Psychopharmacol 18: 457–474
Sallette J, Pons S, villers-Thiery A, Soudant M, Prado de CL, Changeux JP,
Corringer PJ (2005) Nicotine upregulates its own receptors through
enhanced intracellular maturation. Neuron 46: 595–607
Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG (1996) Nico-
tine inhibits amyloid formation by the beta-peptide. Biochemistry 35:
13568–13578
Samaha AN, Robinson TE (2005) Why does the rapid delivery of drugs to
the brain promote addiction? Trends Pharmacol Sci 26: 82–87
Schneider JS, Tinker JP, Menzaghi F, Lloyd GK (2003) The subtype-
selective nicotinic acetylcholine receptor agonist SIB-1553A improves
both attention and memory components of a spatial working memory
task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine-treated monkeys. J Pharmacol Exp Ther 306: 401–406
Seguela P, Wadiche J, neley-Miller K, Dani JA, Patrick JW (1993)
Molecular cloning, functional properties, and distribution of rat brain
alpha 7: a nicotinic cation channel highly permeable to calcium. J
Neurosci 13: 596–604
Semba J, Miyoshi R, Kito S (1996) Nicotine protects against the dexa-
methasone potentiation of kainic acid-induced neurotoxicity in cul-
tured hippocampal neurons. Brain Res 735: 335–338
Shim IS, Won JS, Lee JK, Song DK, Kim SE, Huh SO, Kim YH, Suh HW
(2000) Modulatory effect of ginseng total saponin on dopamine release
and tyrosine hydroxylase gene expression induced by nicotine in the
rat. J Ethnopharmacol 70: 161–169
Shimohama S, Akaike A, Kimura J (1996) Nicotine-induced protection
against glutamate cytotoxicity. Nicotinic cholinergic receptor-
mediated inhibition of nitric oxide formation. Ann NY Acad Sci
777: 356–361
Shimohama S, Kihara T (2001) Nicotinic receptor-mediated protection
against beta-amyloid neurotoxicity. Biol Psychiatry 49: 233–239
Singh IN, Sorrentino G, Sitar DS, Kanfer JN (1998) (–)Nicotine inhibits the
activations of phospholipases A2 and D by amyloid beta peptide. Brain
Res 800: 275–281
Small DH, Mok SS, Bornstein JC (2001) Alzheimer’s disease and Abeta
toxicity: from top to bottom. Nat Rev Neurosci 2: 595–598
Sofroniew MV, Galletly NP, Isacson O, Svendsen CN (1990) Survival of
adult basal forebrain cholinergic neurons after loss of target neurons.
Science 247: 338–342
Stachowiak MK, Moffett J, Joy A, Puchacz E, Florkiewicz R, Stachowiak
EK (1994) Regulation of bFGF gene expression and subcellular
distribution of bFGF protein in adrenal medullary cells. J Cell Biol
127: 203–223
Summers KL, Giacobini E (1995) Effects of local and repeated systemic
administration of (–)nicotine on extracellular levels of acetylcholine,
norepinephrine, dopamine, and serotonin in rat cortex. Neurochem Res
20: 753–759
Summers KL, Kem WR, Giacobini E (1997) Nicotinic agonist modula-
tion of neurotransmitter levels in the rat frontoparietal cortex. Jpn
J Pharmacol 74: 139–146
Sun X, Liu Y, Hu G, Wang H (2004) Protective effects of nicotine against
glutamate-induced neurotoxicity in PC12 cells. Cell Mol Biol Lett 9:
409–422
Sweatt JD (2001) The neuronal MAP kinase cascade: a biochemical sig-
nal integration system subserving synaptic plasticity and memory.
J Neurochem 76: 1–10
Tanabe J, Tregellas JR, Martin LF, Freedman R (2005) Effects of Nicotine
on Hippocampal and Cingulate Activity During Smooth Pursuit Eye
Movement in Schizophrenia. Biol. Psychiatry: PM: 16259965
Tani Y, Saito K, Imoto M, Ohno T (1998) Pharmacological characterization
of nicotinic receptor-mediated acetylcholine release in rat brain-an in
vivo microdialysis study. Eur J Pharmacol 351: 181–188
Toborek M, Garrido R, Malecki A, Kaiser S, Mattson MP, Hennig B, Young
B (2000) Nicotine attenuates arachidonic acid-induced overexpression
of nitric oxide synthase in cultured spinal cord neurons. Exp Neurol
161: 609–620
Tooyama I, Kawamata T, Walker D, Yamada T, Hanai K, Kimura H, Iwane
M, Igarashi K, McGeer EG, McGeer PL (1993) Loss of basic fibroblast
growth factor in substantia nigra neurons in Parkinson’s disease.
Neurology 43: 372–376
Vallejo YF, Buisson B, Bertrand D, Green WN (2005) Chronic nicotine
exposure upregulates nicotinic receptors by a novel mechanism.
J Neurosci 25: 5563–5572
Vernier JM, El-Abdellaoui H, Holsenback H, Cosford ND, Bleicher L,
Barker G, Bontempi B, Chavez-Noriega L, Menzaghi F, Rao TS,
Reid R, Sacaan AI, Suto C, Washburn M, Lloyd GK, McDonald
IA (1999) 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydro-
chloride (SIB-1553A): a novel cognitive enhancer with selectivity
for neuronal nicotinic acetylcholine receptors. J Med Chem 42:
1684–1686
Wada E, McKinnon D, Heinemann S, Patrick J, Swanson LW (1990) The
distribution of mRNA encoded by a new member of the neuronal
nicotinic acetylcholine receptor gene family (alpha 5) in the rat central
nervous system. Brain Res 526: 45–53
Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, Swanson
LW (1989) Distribution of alpha 2, alpha 3, alpha 4, and beta 2
neuronal nicotinic receptor subunit mRNAs in the central nervous
system: a hybridization histochemical study in the rat. J Comp Neurol
284: 314–335
Walters CL, Cleck JN, Kuo YC, Blendy JA (2005) Mu-opioid receptor and
CREB activation are required for nicotine reward. Neuron 46: 933–943
Wang H, Sun X (2005) Desensitized nicotinic receptors in brain. Brain
Res Rev 48: 420–437
Warburton DM, Wesnes K, Shergold K, James M (1986) Facilitation of
learning and state dependency with nicotine. Psychopharmacology
(Berl) 89: 55–59
Wonnacott S (1990) The paradox of nicotinic acetylcholine receptor
upregulation by nicotine. Trends Pharmacol Sci 11: 216–219
Zamani MR, Allen YS (2001) Nicotine and its interaction with beta-
amyloid protein: a short review. Biol Psychiatry 49: 221–232
Nicotinic receptor agonists as neuroprotective=neurotrophic drugs 147
